AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24277961 — intervention group
Group type: COMPARATOR
Intervention: Intranasal midazolam 0.3 mg/kg
Number of subjects: 60
Study 23302459 — intervention group
Group type: EXPERIMENTAL
Intervention: MRS-guided stereotactic biopsy
Number of subjects: 126
Study 23302459 — intervention group
Group type: COMPARATOR
Intervention: MRI-guided stereotactic biopsy
Number of subjects: 126
Study 20219285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sex hormonal treatment in MF transsexuals
Number of subjects: 18
Study 20219285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sex hormonal treatment in FM transsexuals
Number of subjects: 18
Study 20219285 — intervention group
Group type: COMPARATOR
Intervention: Control males
Number of subjects: 18
Study 20219285 — intervention group
Group type: COMPARATOR
Intervention: Control females
Number of subjects: 18
Study 17532158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca
Number of subjects: 0
Study 17532158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17369712 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g/kg BW/day
Number of subjects: 121
Study 17369712 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg BW/day
Number of subjects: 121
Study 17369712 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg BW/day
Number of subjects: 121
Study 17369712 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g/kg BW/day
Number of subjects: 121
Study 17369712 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 g/kg BW/day
Number of subjects: 121
Study 17369712 — intervention group
Group type: COMPARATOR
Intervention: >=0.8 g/kg BW/day
Number of subjects: 121
Study 15487439 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful sound stimuli (noise)
Number of subjects: 17
Study 15487439 — intervention group
Group type: COMPARATOR
Intervention: No noise
Number of subjects: 17
Study 11420762 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 125
Study 11420762 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 125
Study 9445630 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic adjuvant treatment
Number of subjects: 0
Study 9445630 — intervention group
Group type: EXPERIMENTAL
Intervention: New cytotoxic agents (gemcitabine, vinorelbine, topotecan)
Number of subjects: 0
Study 9445630 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with paclitaxel and docetaxel
Number of subjects: 0
Study 9445630 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective aromatase inhibitors, new antigestagens, and antiestrogens
Number of subjects: 0
Study 9445630 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose intensity concepts with growth factors and peripheral stem cell support
Number of subjects: 0
Study 9445630 — intervention group
Group type: EXPERIMENTAL
Intervention: Humanized monoclonal antibody against CerbB‐2 receptors
Number of subjects: 0
Study 8383403 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% combination of alcuronium (0.125 mg.kg‐1) and tubocurarine (0.255 mg.kg‐1)
Number of subjects: 0
Study 8383403 — intervention group
Group type: COMPARATOR
Intervention: Alcuronium alone (0.25 mg.kg‐1)
Number of subjects: 0
Study 8383403 — intervention group
Group type: COMPARATOR
Intervention: Tubocurarine alone (0.51 mg.kg‐1)
Number of subjects: 0
Study 8383403 — intervention group
Group type: COMPARATOR
Intervention: 33% combination of alcuronium and tubocurarine
Number of subjects: 0
Study 3549739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic administration of protamine sulphate
Number of subjects: 20
Study 3549739 — intervention group
Group type: COMPARATOR
Intervention: Intra-right atrial administration of protamine sulphate
Number of subjects: 20
Study 31347012 — intervention group
Group type: EXPERIMENTAL
Intervention: dDAVP (lyophilizate 120 μg)
Number of subjects: 100
Study 31347012 — intervention group
Group type: EXPERIMENTAL
Intervention: New age- and weight-based dosing regimen
Number of subjects: 100
Study 29952004 — intervention group
Group type: EXPERIMENTAL
Intervention: UTTR1147A (IL-22Fc) administered intravenously (i.v.) at doses of 1-120 μg/kg
Number of subjects: 0
Study 29952004 — intervention group
Group type: EXPERIMENTAL
Intervention: UTTR1147A (IL-22Fc) administered subcutaneously (s.c.) at doses of 3-120 μg/kg
Number of subjects: 0
Study 29952004 — intervention group
Group type: EXPERIMENTAL
Intervention: UTTR1147A (IL-22Fc)
Number of subjects: 0
Study 29952004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28086766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention, consisting of 6 sessions (1 individual and 5 group) offered by a psychologist, in addition to treatment as usual.
Number of subjects: 600
Study 28086766 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group).
Number of subjects: 600
Study 26101366 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine (3-dose regimen at day 1, month 2, month 6)
Number of subjects: 3066
Study 23703247 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 70
Study 23703247 — intervention group
Group type: COMPARATOR
Intervention: FOLFOXIRI/XELOXIRI
Number of subjects: 70
Study 21878824 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance followed by aerobic exercise (R‐A)
Number of subjects: 7
Study 21878824 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic followed by resistance exercise (A‐R)
Number of subjects: 7
Study 21878824 — intervention group
Group type: COMPARATOR
Intervention: Both R‐A and A‐R
Number of subjects: 7
Study 21878824 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐R
Number of subjects: 7
Study 19490293 — intervention group
Group type: EXPERIMENTAL
Intervention: Lindsay Leg Club model of care
Number of subjects: 67
Study 19490293 — intervention group
Group type: COMPARATOR
Intervention: Traditional community nursing model
Number of subjects: 67
Study 17065355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 2748
Study 17065355 — intervention group
Group type: COMPARATOR
Intervention: Blood glucose >150 mg/dl
Number of subjects: 2748
Study 17065355 — intervention group
Group type: COMPARATOR
Intervention: Blood glucose <110 mg/dl
Number of subjects: 2748
Study 17065355 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 2748
Study 15170708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab treatment
Number of subjects: 45
Study 15170708 — intervention group
Group type: COMPARATOR
Intervention: Usual abciximab administration
Number of subjects: 45
Study 11641678 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (25 microg vaginally on days 1 and 4)
Number of subjects: 120
Study 11641678 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vaginally on days 1 and 4)
Number of subjects: 120
Study 11641678 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 120
Study 11641678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9841947 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with ePTFE membranes
Number of subjects: 20
Study 9841947 — intervention group
Group type: COMPARATOR
Intervention: Conventional flap surgery (previous treatment)
Number of subjects: 20
Study 9841947 — intervention group
Group type: COMPARATOR
Intervention: Matched control patients who underwent conventional treatment alone
Number of subjects: 20
Study 8135881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular glucosamine sulfate 400 mg twice a week for 6 weeks
Number of subjects: 155
Study 8135881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 2913766 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 12
Study 2913766 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 12
Study 31138140 — intervention group
Group type: COMPARATOR
Intervention: Support staff
Number of subjects: 882
Study 31138140 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate numbers of disposable respirators
Number of subjects: 882
Study 31138140 — intervention group
Group type: EXPERIMENTAL
Intervention: TB stigma scale
Number of subjects: 882
Study 28680341 — intervention group
Group type: EXPERIMENTAL
Intervention: One night sleep deprivation
Number of subjects: 64
Study 28680341 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep
Number of subjects: 64
Study 26307858 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for chronic neuropathic pain
Number of subjects: 0
Study 26307858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26307858 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment
Number of subjects: 0
Study 23543140 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin (8 mg/daily for a maximum of 4 weeks)
Number of subjects: 112
Study 23543140 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 L of water daily)
Number of subjects: 112
Study 22368896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 107
Study 22368896 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin/clavulanate
Number of subjects: 107
Study 19436289 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding metal stents (SEMSs)
Number of subjects: 215
Study 19436289 — intervention group
Group type: COMPARATOR
Intervention: Non-stent treatments
Number of subjects: 215
Study 16454836 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (60 to 120 mg tablet once a day)
Number of subjects: 76
Study 16454836 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tablet once a day)
Number of subjects: 76
Study 15039128 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive pharmacological treatment (using statins, beta-blockers, ACE-inhibitors, and aspirin)
Number of subjects: 100
Study 15039128 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-wide reductions in serum total cholesterol and systolic blood pressure
Number of subjects: 100
Study 12604023 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of zafirlukast twice a day
Number of subjects: 36
Study 12604023 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of budesonide twice a day
Number of subjects: 36
Study 12604023 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of zafirlukast twice a day and 400 mg of budesonide twice a day
Number of subjects: 36
Study 12604023 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 healthy subjects)
Number of subjects: 36
Study 9306141 — intervention group
Group type: EXPERIMENTAL
Intervention: AWOS QCA system
Number of subjects: 57
Study 9306141 — intervention group
Group type: COMPARATOR
Intervention: Cardio QCA system
Number of subjects: 57
Study 9306141 — intervention group
Group type: COMPARATOR
Intervention: CMS QCA system
Number of subjects: 57
Study 9306141 — intervention group
Group type: COMPARATOR
Intervention: Brown Dodge method
Number of subjects: 57
Study 8232703 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture applied 3 times/week for 4 weeks
Number of subjects: 30
Study 8232703 — intervention group
Group type: COMPARATOR
Intervention: Conventional supportive treatment
Number of subjects: 30
Study 2446759 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine (50 mg/kg) as pulse immunotherapy, schedule A: 5 days every 15 days
Number of subjects: 0
Study 2446759 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine (50 mg/kg) as pulse immunotherapy, schedule B: 5 days every 15 days for 2 months, then 5 days every 2 months
Number of subjects: 0
Study 2446759 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 30213617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=5) received weekly boxes of fruits and vegetables and dietary counseling to increase consumption to 8 to 10 daily servings for 12 weeks.
Number of subjects: 10
Study 30213617 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=5) directed to the USDA's 'ChooseMyPlate' diet for pregnancy and breastfeeding.
Number of subjects: 10
Study 30213617 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups measured cytokine levels in breast milk at weeks 1 and 13.
Number of subjects: 10
Study 28114849 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function under stress
Number of subjects: 110
Study 28114849 — intervention group
Group type: COMPARATOR
Intervention: Control task (non-stressful context)
Number of subjects: 110
Study 26849552 — intervention group
Group type: EXPERIMENTAL
Intervention: International Physical Activity Questionnaire (IPAQ) in 2002
Number of subjects: 2751
Study 26849552 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Physical Activity Questionnaire (GPAQ) in 2011
Number of subjects: 2751
Study 23300039 — intervention group
Group type: COMPARATOR
Intervention: Conventional CTA (Group A)
Number of subjects: 62
Study 23300039 — intervention group
Group type: EXPERIMENTAL
Intervention: CTA with novel OSDR algorithm (Group B)
Number of subjects: 62
Study 20834044 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (100 mg)
Number of subjects: 12
Study 20834044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18342559 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg sildenafil
Number of subjects: 18
Study 18342559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16824221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 42
Study 16824221 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 42
Study 14600926 — intervention group
Group type: EXPERIMENTAL
Intervention: CK‐MB increase > 50 IU/ml (group 1, n = 9)
Number of subjects: 36
Study 14600926 — intervention group
Group type: COMPARATOR
Intervention: CK‐MB levels </= 50 IU/ml (group 2, n = 27)
Number of subjects: 36
Study 14600926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 36
Study 14600926 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (CK‐MB > 50 IU/ml)
Number of subjects: 36
Study 14600926 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (CK‐MB </= 50 IU/ml)
Number of subjects: 36
Study 14600926 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased CK‐MB level
Number of subjects: 36
Study 14600926 — intervention group
Group type: EXPERIMENTAL
Intervention: New defect of perfusion found at follow-up MPI
Number of subjects: 36
Study 10831545 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (triptorelin) with HMG
Number of subjects: 0
Study 10831545 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (buserelin) with HMG
Number of subjects: 0
Study 10831545 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonists (triptorelin or buserelin) with HMG
Number of subjects: 0
Study 10831545 — intervention group
Group type: COMPARATOR
Intervention: HMG alone
Number of subjects: 0
Study 9104522 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg granisetron (approximately 60 micrograms.kg‐1)
Number of subjects: 80
Study 9104522 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg droperidol (approximately 25 micrograms.kg‐1)
Number of subjects: 80
Study 9104522 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study 8182634 — intervention group
Group type: EXPERIMENTAL
Intervention: Home physiotherapy treatment program
Number of subjects: 46
Study 8182634 — intervention group
Group type: COMPARATOR
Intervention: Control group (previously withheld treatment)
Number of subjects: 46
Study 3372681 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg orally) + Alcohol
Number of subjects: 14
Study 3372681 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (50 mg orally) + Placebo
Number of subjects: 14
Study 3372681 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg orally)
Number of subjects: 14
Study 31063475 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) and Sofosbuvir (SOF) therapy
Number of subjects: 132
Study 28163113 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive or sunflower oil yarrow extracts applied topically for seven days
Number of subjects: 0
Study 28163113 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25160493 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium aluminosilicate clay (CASAD)
Number of subjects: 100
Study 25160493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23238657 — intervention group
Group type: EXPERIMENTAL
Intervention: AGE‐modified β‐lactoglobulins (AGE‐BLG)
Number of subjects: 19
Study 23238657 — intervention group
Group type: COMPARATOR
Intervention: Heat‐treated, nonglycated β‐lactoglobulins (C‐BLG)
Number of subjects: 19
Study 21572353 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle damage group (plyometric exercise)
Number of subjects: 17
Study 18420373 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulators
Number of subjects: 0
Study 18420373 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 18420373 — intervention group
Group type: EXPERIMENTAL
Intervention: Criterion scores
Number of subjects: 0
Study 16405734 — intervention group
Group type: EXPERIMENTAL
Intervention: Drip-push (4 modules weekly over 10 weeks by email)
Number of subjects: 1267
Study 16405734 — intervention group
Group type: EXPERIMENTAL
Intervention: Drip-pull (modules accessible on website with 4 reminders weekly for 10 weeks)
Number of subjects: 1267
Study 16405734 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus-push (40 modules delivered within 4 days by email)
Number of subjects: 1267
Study 16405734 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus-pull (40 modules available on the Internet with one email informing participants of availability)
Number of subjects: 1267
Study 14609565 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 26
Study 14609565 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia plus Thoracic Epidural Block (TEB)
Number of subjects: 26
Study 12922085 — intervention group
Group type: EXPERIMENTAL
Intervention: Full adult dose of tick-borne encephalitis vaccine
Number of subjects: 595
Study 12922085 — intervention group
Group type: EXPERIMENTAL
Intervention: Half adult dose of tick-borne encephalitis vaccine
Number of subjects: 595
Study 10381173 — intervention group
Group type: EXPERIMENTAL
Intervention: rgp160
Number of subjects: 124
Study 10381173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 8678275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (S)
Number of subjects: 40
Study 8678275 — intervention group
Group type: COMPARATOR
Intervention: Halothane (H)
Number of subjects: 40
Study 1832424 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g glucose dose
Number of subjects: 7
Study 1832424 — intervention group
Group type: COMPARATOR
Intervention: sham control (distilled water)
Number of subjects: 7
Study 6388716 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephazolin (given either pre‐operatively or into the wound)
Number of subjects: 375
Study 6388716 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 375
Study 3527371 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 12
Study 3527371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31081224 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 275
Study 31081224 — intervention group
Group type: COMPARATOR
Intervention: Peer modelling (high vs. low)
Number of subjects: 275
Study 29053645 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed drilling with irrigation
Number of subjects: 25
Study 29053645 — intervention group
Group type: COMPARATOR
Intervention: Low-speed drilling without irrigation
Number of subjects: 25
Study 24267102 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Care (EC)
Number of subjects: 105
Study 24267102 — intervention group
Group type: COMPARATOR
Intervention: Supported Care (SC)
Number of subjects: 105
Study 23277234 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 71
Study 23277234 — intervention group
Group type: COMPARATOR
Intervention: Placebo responders
Number of subjects: 71
Study 23277234 — intervention group
Group type: COMPARATOR
Intervention: Placebo nonresponders
Number of subjects: 71
Study 20852882 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral leg immobilization for 12 days
Number of subjects: 15
Study 18438908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative prednisone dosage in multiple flares subgroup: 7.9 gm
Number of subjects: 168
Study 18438908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative prednisone dosage in single flare subgroup: 6.0 gm
Number of subjects: 168
Study 18438908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative prednisone dosage in remission subgroup: 3.9 gm
Number of subjects: 168
Study 18438908 — intervention group
Group type: EXPERIMENTAL
Intervention: New diagnosis of Wegener's granulomatosis at baseline
Number of subjects: 168
Study 18438908 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in remission subgroup (40 patients)
Number of subjects: 168
Study 18438908 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall weight gain >10 kg
Number of subjects: 168
Study 16854754 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low-dose azathioprine (0.6-0.75 mg/kg) and oral PUVA therapy
Number of subjects: 60
Study 16854754 — intervention group
Group type: COMPARATOR
Intervention: Oral PUVA therapy alone
Number of subjects: 60
Study 15331546 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric inhibitory polypeptide (GIP) infusion (2 pmol. kg(‐1). min(‐1), 60‐115 min)
Number of subjects: 13
Study 15331546 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion
Number of subjects: 13
Study 15331546 — intervention group
Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 13
Study 11557836 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced-deficit diets
Number of subjects: 108
Study 11557836 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diets
Number of subjects: 108